The rise of counterfeit drugs has become a critical issue in the pharmaceutical industry, particularly with the soaring demand for weight-loss therapies like Novo Nordisk's Wegovy. As the company battles to protect its intellectual property and patient safety, its actions in 2025 reveal a broader shift toward risk mitigation in drug distribution and a market consolidation around FDA-approved therapies. For investors, this strategy carries both risks and opportunities, reshaping the landscape for telehealth partnerships and regulatory compliance.
Read Full Article
#Counterfeit
#RiskMitigation
#Compliance